866-997-4948(US-Canada Toll Free)

Oral Mucositis - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 72 Pages


Global Markets Directs, \'Oral Mucositis Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Oral Mucositis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oral Mucositis. 

Oral Mucositis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Oral Mucositis.
  • A review of the Oral Mucositis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Oral Mucositis pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Oral Mucositis.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Oral Mucositis pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Oral Mucositis Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Oral Mucositis 8
Oral Mucositis Therapeutics under Development by Companies 10
Oral Mucositis Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Oral Mucositis Therapeutics - Products under Development by Companies 17
Oral Mucositis Therapeutics - Products under Investigation by Universities/Institutes 18
Companies Involved in Oral Mucositis Therapeutics Development 19
Daewoong Pharmaceutical Co., Ltd. 19
Sucampo Pharmaceuticals, Inc. 20
PolyMedix, Inc. 21
ActogeniX NV 22
Alder Biopharmaceuticals Inc. 23
GliaMed, Inc. 24
Avaxia Biologics, Inc. 25
Canopus BioPharma Incorporated 26
Nephrx Corporation 27
Applied Protein Sciences, LLC 28
Oral Mucositis - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
GM-1485 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
AG-013 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
nepidermin - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
cobiprostone - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
clazakizumab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
brilacidin - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
oltipraz - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
NX-002 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Hybrid Adenoretroviral Vectors - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Regenasyn - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Lactobacillus CD2 Lozenges - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
GC-4419 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AP-002 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
AP-001 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Oral Mucositis Therapeutics - Drug Profile Updates 53
Oral Mucositis Therapeutics - Discontinued Products 61
Oral Mucositis Therapeutics - Dormant Products 62
Oral Mucositis - Product Development Milestones 63
Featured News & Press Releases 63
Sep 19, 2012: PolyMedix Receives Grant From National Cancer Institute To Study Brilacidin For Oral Mucositis 63
Aug 22, 2012: ActoGeniX Announces Positive Results From Phase I Study Of AG013 For Prevention Of Oral Mucositis In Cancer Patients 64
Jul 20, 2012: Piramal Healthcare Receives Approval For Conducting Phase II Clinical Trial Of P276 64
Jun 28, 2012: Access Pharma Announces Positive Data From MuGard Phase IV Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium 65
Jun 26, 2012: Access Pharma To Report New MuGard Clinical Trial Data At MASCC/ISOO Symposium 67
Apr 17, 2012: BioAlliance Pharma Announces New Achievements In Phase II Clinical Trial Of Clonidine Lauriad 67
Apr 17, 2012: Access Pharma Announces Interim Data From MuGard Phase IV Clinical Trial In Oral Mucositis 68
Apr 04, 2012: Access Pharmaceuticals Announces Addition Of MuGard On Formulary At Memorial Sloan-Kettering Cancer Center 69
Mar 02, 2012: SciClone Announces Results Of Interim Analysis Of Phase II SCV-07 Oral Mucositis Trial 69
Feb 24, 2012: Rhei Pharmaceuticals Receives Final Marketing Approval From SFDA Of China For MuGard 70

Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 72
Disclaimer 72

List of Table


Number of Products Under Development for Oral Mucositis, H1 2013 8
Products under Development for Oral Mucositis - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 11
Number of Products under Investigation by Universities/Institutes, H1 2013 12
Comparative Analysis by Late Stage Development, H1 2013 13
Comparative Analysis by Mid Clinical Stage Development, H1 2013 14
Comparative Analysis by Early Clinical Stage Development, H1 2013 15
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 16
Products under Development by Companies, H1 2013 17
Products under Investigation by Universities/Institutes, H1 2013 18
Daewoong Pharmaceutical Co., Ltd., H1 2013 19
Sucampo Pharmaceuticals, Inc., H1 2013 20
PolyMedix, Inc., H1 2013 21
ActogeniX NV, H1 2013 22
Alder Biopharmaceuticals Inc., H1 2013 23
GliaMed, Inc., H1 2013 24
Avaxia Biologics, Inc., H1 2013 25
Canopus BioPharma Incorporated, H1 2013 26
Nephrx Corporation, H1 2013 27
Applied Protein Sciences, LLC, H1 2013 28
Assessment by Monotherapy Products, H1 2013 29
Assessment by Stage and Route of Administration, H1 2013 31
Assessment by Stage and Molecule Type, H1 2013 33
Oral Mucositis Therapeutics - Drug Profile Updates 53
Oral Mucositis Therapeutics - Discontinued Products 61
Oral Mucositis Therapeutics - Dormant Products 62

List of Chart


Number of Products under Development for Oral Mucositis, H1 2013 8
Products under Development for Oral Mucositis - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Products under Investigation by Universities/Institutes, H1 2013 12
Late Stage Products, H1 2013 13
Mid Clinical Stage Products, H1 2013 14
Early Clinical Stage Products, H1 2013 15
Pre-Clinical Stage Products, H1 2013 16
Assessment by Monotherapy Products, H1 2013 29
Assessment by Route of Administration, H1 2013 30
Assessment by Stage and Route of Administration, H1 2013 31
Assessment by Molecule Type, H1 2013 32
Assessment by Stage and Molecule Type, H1 2013 33

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *